Drug Profile
Research programme: selective androgen receptor modulators - ACADIA Pharmaceuticals
Alternative Names: ACP-105; SARMs - ACADIA PharmaceuticalsLatest Information Update: 04 Apr 2012
Price :
$50
*
At a glance
- Originator ACADIA Pharmaceuticals
- Class Small molecules
- Mechanism of Action Selective androgen receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Andropause; Muscular atrophy; Osteoporosis
Most Recent Events
- 31 Dec 2010 No development reported - Preclinical for Andropause in USA (PO)
- 31 Dec 2010 No development reported - Preclinical for Muscular atrophy in USA (PO)
- 31 Dec 2010 No development reported - Preclinical for Osteoporosis in USA (PO)